Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC - PubMed
3 hours ago
- #Clinical Trial
- #NSCLC
- #EGFR-mutated
- Study evaluates amivantamab-lazertinib combination in EGFR-mutated advanced NSCLC.
- Clinical trial results published in the New England Journal of Medicine.
- Findings indicate potential benefits in overall survival for patients.
- Multinational research effort involving numerous investigators and institutions.